BACKGROUND: Lung inflammation precedes the development of hypoxia-induced pulmonary hypertension (HPH); however, its role in the pathogenesis of HPH is poorly understood. We sought to characterize the hypoxic inflammatory response and to elucidate its role in the development of HPH. We also aimed to investigate the mechanisms by which heme oxygenase-1, an anti-inflammatory enzyme, is protective in HPH. METHODS AND RESULTS: We generated bitransgenic mice that overexpress human heme oxygenase-1 under doxycycline control in an inducible, lung-specific manner. Hypoxic exposure of mice in the absence of doxycycline resulted in early transient accumulation of monocytes/macrophages in the bronchoalveolar lavage. Alveolar macrophages acquired an alternatively activated phenotype (M2) in response to hypoxia, characterized by the expression of found in inflammatory zone-1, arginase-1, and chitinase-3-like-3. A brief 2-day pulse of doxycycline delayed, but did not prevent, the peak of hypoxic inflammation, and could not protect against HPH. In contrast, a 7-day doxycycline treatment sustained high heme oxygenase-1 levels during the entire period of hypoxic inflammation, inhibited macrophage accumulation and activation, induced macrophage interleukin-10 expression, and prevented the development of HPH. Supernatants from hypoxic M2 macrophages promoted the proliferation of pulmonary artery smooth muscle cells, whereas treatment with carbon monoxide, a heme oxygenase-1 enzymatic product, abrogated this effect. CONCLUSIONS: Early recruitment and alternative activation of macrophages in hypoxic lungs are critical for the later development of HPH. Heme oxygenase-1 may confer protection from HPH by effectively modifying the macrophage activation state in hypoxia.
BACKGROUND:Lung inflammation precedes the development of hypoxia-induced pulmonary hypertension (HPH); however, its role in the pathogenesis of HPH is poorly understood. We sought to characterize the hypoxic inflammatory response and to elucidate its role in the development of HPH. We also aimed to investigate the mechanisms by which heme oxygenase-1, an anti-inflammatory enzyme, is protective in HPH. METHODS AND RESULTS: We generated bitransgenic mice that overexpress humanheme oxygenase-1 under doxycycline control in an inducible, lung-specific manner. Hypoxic exposure of mice in the absence of doxycycline resulted in early transient accumulation of monocytes/macrophages in the bronchoalveolar lavage. Alveolar macrophages acquired an alternatively activated phenotype (M2) in response to hypoxia, characterized by the expression of found in inflammatory zone-1, arginase-1, and chitinase-3-like-3. A brief 2-day pulse of doxycycline delayed, but did not prevent, the peak of hypoxic inflammation, and could not protect against HPH. In contrast, a 7-day doxycycline treatment sustained high heme oxygenase-1 levels during the entire period of hypoxic inflammation, inhibited macrophage accumulation and activation, induced macrophage interleukin-10 expression, and prevented the development of HPH. Supernatants from hypoxic M2 macrophages promoted the proliferation of pulmonary artery smooth muscle cells, whereas treatment with carbon monoxide, a heme oxygenase-1 enzymatic product, abrogated this effect. CONCLUSIONS: Early recruitment and alternative activation of macrophages in hypoxic lungs are critical for the later development of HPH. Heme oxygenase-1 may confer protection from HPH by effectively modifying the macrophage activation state in hypoxia.
Authors: T Minamino; H Christou; C M Hsieh; Y Liu; V Dhawan; N G Abraham; M A Perrella; S A Mitsialis; S Kourembanas Journal: Proc Natl Acad Sci U S A Date: 2001-07-10 Impact factor: 11.205
Authors: Yi Jin; Thomas J Calvert; Bernadette Chen; Louis G Chicoine; Mandar Joshi; John Anthony Bauer; Yusen Liu; Leif D Nelin Journal: Am J Physiol Heart Circ Physiol Date: 2010-02-19 Impact factor: 4.733
Authors: F A Wagener; A Eggert; O C Boerman; W J Oyen; A Verhofstad; N G Abraham; G Adema; Y van Kooyk; T de Witte; C G Figdor Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: S Inoue; M Suzuki; Y Nagashima; S Suzuki; T Hashiba; T Tsuburai; K Ikehara; T Matsuse; Y Ishigatsubo Journal: Hum Gene Ther Date: 2001-05-20 Impact factor: 5.695
Authors: Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-02-03 Impact factor: 5.464
Authors: Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman Journal: Circ Res Date: 2018-12-07 Impact factor: 17.367
Authors: Andrew J Bryant; Vinayak Shenoy; Chunhua Fu; George Marek; Kyle J Lorentsen; Erica L Herzog; Mark L Brantly; Dorina Avram; Edward W Scott Journal: Am J Respir Cell Mol Biol Date: 2018-02 Impact factor: 6.914
Authors: Min Li; Suzette Riddle; Hui Zhang; Angelo D'Alessandro; Amanda Flockton; Natalie J Serkova; Kirk C Hansen; Radu Moldovan; B Alexandre McKeon; Maria Frid; Sushil Kumar; Hong Li; Hongbing Liu; Angela Caánovas; Juan F Medrano; Milton G Thomas; Dijana Iloska; Lydie Plecitá-Hlavatá; Petr Ježek; Soni Pullamsetti; Mehdi A Fini; Karim C El Kasmi; QingHong Zhang; Kurt R Stenmark Journal: Circulation Date: 2016-08-25 Impact factor: 29.690
Authors: Leah R Villegas; Dylan Kluck; Carlie Field; Rebecca E Oberley-Deegan; Crystal Woods; Michael E Yeager; Karim C El Kasmi; Rashmin C Savani; Russell P Bowler; Eva Nozik-Grayck Journal: Antioxid Redox Signal Date: 2013-02-05 Impact factor: 8.401